
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is poised for continued growth thanks to the positive results of its CGM systems in both clinical trials and real-world usage. The company has a strong product pipeline and a solid management team, and its innovative technology sets it apart in the market. DexCom's involvement in the T2NIT coverage expansion initiative puts it in a prime position to benefit from the potential adoption of CGM systems in the non-insulin type 2 diabetes population. However, there are potential risks to the diabetes device sector, such as regulatory processes and potential pricing pressures, that investors should consider. Based on the company's recent financial performance and its potential for future growth, a Buy rating is appropriate with a price target of $75.
Bears say
DexCom is facing pricing headwinds in the short and long term due to market dynamics and competition, as well as potential regulatory hurdles that could delay new product releases. However, the company has a strong market position with its top-tier management team and a profitable model, making it a leader in the continuous glucose monitoring market. Risks of low CGM adoption and potential disruptions from competitors exist, but DXCM's robust pipeline provides potential upside for revenue and profit in the future.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares